CD8A and neoplasm: Furthermore, a separate study confirmed that anti-CD47 antibodies exert tumor-killing effects through the activation of CD8+ T-cells and dendritic cells (73), which phagocytose tumor cells and process specific antigens that lead to presentation of tumor cells to CD8+ T-cells, thereby activating tumor cell-specific adaptive immunity (73).